8-K: Intelligent Bio Solutions Drug Test Shows High Accuracy

Intelligent Bio Solutions Inc. announced strong results from a method comparison study for its Intelligent Fingerprinting Drug Screening System, achieving over 98% accuracy for detecting codeine.

Summary

• Intelligent Bio Solutions Inc. has announced positive results from a multi-site Method Comparison Study for its Intelligent Fingerprinting Drug Screening System, specifically for detecting the opiate codeine.
• The study, conducted across three independent U.S. clinical sites, demonstrated substantial performance improvements compared to a previous study in November 2024.
• Key findings include an overall accuracy of 98.2%, sensitivity above 94% (specifically 94.6%), and 100% specificity.
• These results were measured against a validated LC-MS/MS reference method.
• The company plans to use these results for its FDA 510(k) submission, which is now on track for September 2026.
• This submission is a critical step for planned entry into the U.S. market.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, with strong study results supporting a key regulatory submission and market entry.

Positives

• Achieved overall accuracy of 98.2% in the Method Comparison Study.
• Demonstrated sensitivity above 94% (94.6%) for detecting codeine.
• Maintained 100% specificity, confirming the system's ability to avoid false positives.
• Results show substantial improvement over the previous study (approx. 94% accuracy, 82% sensitivity).
• The study data is now complete and supports the planned FDA 510(k) submission.
• The 510(k) submission is accelerated and expected in September 2026.
• The system is described as hygienic, cost-effective, and capable of rapid results (under ten minutes).

Negatives

• While sensitivity improved significantly, it is still a key area of focus for future development.
• The filing does not provide specific financial figures related to the study or its impact on revenue.

Risks

• The company's ability to successfully develop and commercialize its drug and diagnostic tests.
• Securing regulatory clearance or approvals from the FDA.
• Timelines to enter the U.S. market.
• Potential for future results to differ materially from forward-looking statements.
• Unknown risks, uncertainties, and other factors as described in public filings with the SEC.

Future Outlook

The company expects to submit its FDA 510(k) application in September 2026, which is a critical step for its planned entry into the U.S. market following FDA clearance. The successful completion of the method comparison study provides the necessary data for this submission.

Management Comments

• "These results have been a long time in the making," said Harry Simeonidis, President and CEO of Intelligent Bio Solutions.
• "Our System was already delivering 100% specificity, but we knew we needed to close the gap on sensitivity. Moving from approximately 82% sensitivity to above 94%, and in doing so lifting our overall accuracy to above 98%, is the outcome we were working toward."
• "With this study complete, we now have everything we need for our 510(k) submission, which remains on track for submittal in calendar 2026."

Industry Context

StockSavvy.ai notes that the medical technology sector, particularly in diagnostics and rapid testing, is highly competitive and driven by regulatory approvals and clinical validation. The strong performance data for Intelligent Bio Solutions' system positions it to potentially gain market share in workplace drug screening, an area with ongoing demand for accurate and efficient solutions.

Stakeholder Impact

• Shareholders: Positive impact expected from progress towards U.S. market entry and potential for increased revenue and market share.
• Employers/Customers: Potential for a more accurate, efficient, and hygienic drug screening solution, reducing false positives and improving workplace safety.
• Employees: Indirect impact through potentially safer work environments in industries utilizing the drug screening system.

Next Steps

• Submit the FDA 510(k) application in September 2026.
• Seek FDA clearance for the Intelligent Fingerprinting Drug Screening System.
• Plan entry into the U.S. market following FDA clearance.

Key Dates

Recommendation

The filing presents strong clinical study results that are crucial for FDA submission and U.S. market entry. While positive, the actual market penetration and financial impact are still future events contingent on regulatory approval and commercial execution. Therefore, a 'hold' recommendation is appropriate, awaiting further developments post-FDA clearance.

Keywords

drug screening, fingerprint analysis, opiate detection, FDA 510(k), method comparison study, clinical study, medical technology, non-invasive testing